© WHO/Yoshi Shimizu
© Credits

Influenza (avian and other zoonotic)

    Overview

    Animal influenza viruses are distinct from human seasonal influenza viruses and do not easily transmit between humans. However, zoonotic influenza viruses - animal influenza viruses that may occasionally infect humans through direct or indirect contact - can cause disease in humans ranging from a mild illness to death.

    Birds are the natural hosts for avian influenza viruses. After an outbreak of A(H5N1) virus in 1997 in poultry in Hong Kong SAR, China, since 2003, this avian and other influenza viruses have spread from Asia to Europe and Africa. In 2013, human infections with the influenza A(H7N9) virus were reported in China.

    Most swine influenza viruses do not cause disease in humans, but some countries have reported cases of human infection from certain swine influenza viruses. Close proximity to infected pigs or visiting locations where pigs are exhibited has been reported for most human cases, but some limited human-to-human transmission has occurred.

    Just like birds and pigs, other animals such as horses and dogs, can be infected with their own influenza viruses (canine influenza viruses, equine influenza viruses, etc.).

    Symptoms

    Avian, swine and other zoonotic influenza infections in humans may cause disease ranging from mild upper respiratory infection (fever and cough) to rapid progression to severe pneumonia, acute respiratory distress syndrome, shock and even death.

    Gastrointestinal symptoms such as nausea, vomiting and diarrhea has been reported more frequently in A(H5N1) infection. Conjunctivitis has also been reported in influenza A(H7).

    Disease features such as the incubation period, severity of symptoms and clinical outcome varies by the virus causing infection but mainly manifests with respiratory symptoms.

    Treatment

    Evidence suggests that some antiviral drugs, notably neuraminidase inhibitor (oseltamivir, zanamivir), can reduce the duration of viral replication and improve prospects of survival, however ongoing clinical studies are needed. Emergence of oseltamivir resistance has been reported.

    News

    All →

    Publications

    All →
    Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III 2024-2030 

    The Pandemic Influenza Preparedness (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the...

    Technical consultation on public health and social measures for mitigating the risk and impact of epidemic and pandemic influenza to update the 2019 WHO guidance

    In the early stages of an influenza pandemic, public health and social measures (PHSM) represent the only readily available non-medical countermeasures...

    Pandemic influenza severity assessment (‎PISA)‎: a WHO guide to assess the severity of influenza in seasonal epidemics and pandemics, second edition

    The updated WHO pandemic influenza severity assessment (PISA) framework set out in this document provides a systematic approach for interpreting data...

    Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III 2024-2030: monitoring and evaluation framework

     The Pandemic Influenza Preparedness (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the strategy...

    Videos

    All →